
|Videos|August 7, 2015
Clinical Trials: Pros and Cons
Advertisement
Advertisement
Related to this article

An expert at ESMO 2026 explains how liquid biopsy and ESR1 testing can help guide treatment for people with HR-positive metastatic breast cancer.

After 19 years of survivorship, one cancer survivor reflects on life's changing seasons, managing scan anxiety and finding support beyond treatment.

Psychiatrist Dr. Yesne Alici of Memorial Sloan Kettering Cancer Center answers questions about family relationships during cancer, from asking for help to talking with children and friends.

Among more than 12,000 cancer survivors 65 and older, those who stayed physically active after diagnosis tended to have lower health care costs, an American Cancer Society study published Oct. 21, 2026, in CANCER found.

The FDA grants traditional approval to Keytruda and Keytruda Qlex for TMB-H solid tumors, updating the threshold to at least 13 mutations per megabase.

Martha Carlson reflects on her 11 years with metastatic breast cancer and explores how resilience, purpose and the stories we tell ourselves shape the cancer experience.

A study found that 1 in 9 older cancer survivors developed a second cancer, highlighting why routine screening remains important beyond five years.
Advertisement
Advertisement
Trending on CURE
1
FDA Grants Traditional Approval to Keytruda for TMB-H Solid Tumors
2
Psychiatrist Answers Questions About Family and Relationships During Cancer
3
FDA Clears AI Tool Using MRI to Gauge Breast Cancer Recurrence
4
What Liquid Biopsy and ESR1 Mutations Mean in Breast Cancer
5




